SAN ANTONIO, Dec. 5, 2017 /PRNewswire/ — Research presented today by Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, shows how clinicians are using genetic testing beyond BRCA1 and BRCA2 to guide treatment and screening decisions for hereditary…
